Sensitivity

QSM Diagnostics Enters Distribution Agreement with Cenversa

Retrieved on: 
Thursday, December 14, 2023

BOSTON, Dec. 14, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Cenversa the parent company of Cenquip Pty Ltd, Australia's leader in innovative veterinary equipment and digital imaging solutions for animal health professionals.

Key Points: 
  • BOSTON, Dec. 14, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics , a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Cenversa the parent company of Cenquip Pty Ltd, Australia's leader in innovative veterinary equipment and digital imaging solutions for animal health professionals.
  • "At Cenversa, we are always looking to innovate when it comes to animal care and health.
  • That's why it is very important for us to have a strategic partner like QSM Diagnostics, as we recognize the importance of proper and timely diagnosis of bacterial infections.
  • "We're very excited to partner with Cenversa and their amazing team," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 9, 2023

WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

Key Points: 
  • WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.
  • Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.
  • Research and development expenses were $10.3 million for the quarter ended September 30, 2023 compared to $7.9 million for the same period in 2022.
  • General and administrative expenses were $5.9 million for the quarter ended September 30, 2023 compared to $1.6 million for the same period in 2022.

bioMérieux Partners with Industry-Leading Yeast Supplier White Labs to Develop GENE-UP® BREWPRO™ Yeast Slurry (YS) - The First Quality Control Test Kit for Yeast-Specific Applications

Retrieved on: 
Tuesday, October 24, 2023

CHICAGO, Oct. 24, 2023 /PRNewswire/ -- bioMérieux, a world leader in in vitro diagnostics, announces the launch of GENE-UP® BREWPRO™ Yeast Slurry (YS) - the first-of-its-kind diagnostic quality control PCR test designed to specifically detect contaminants in raw yeast materials and yeast propagations to ensure top quality fermentations. Developed in collaboration with industry-leading yeast supplier White Labs, the solution features an optimized sample prep with increased sensitivity and specialized targets tailor-made for yeast slurries.

Key Points: 
  • Developed in collaboration with industry-leading yeast supplier White Labs , the solution features an optimized sample prep with increased sensitivity and specialized targets tailor-made for yeast slurries.
  • GENE-UP® BREWPRO™ YS is the first diagnostic quality control PCR test designed for raw yeast materials and propagations.
  • Yeast suppliers and brewers producing their own yeast must navigate numerous spoilage and unwanted bacteria and contamination challenges throughout the harvesting and yeast propagation processes.
  • Current quality control test kits for the brewing industry are designed to detect potential spoilers in the finished product, not in the yeast slurries themselves.

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, October 16, 2023

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) --  Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, announced data highlighting its AP3 approach to identify and evaluate biomarkers for its OncoSignature assay designed specifically to predict sensitivity to ACR-368, the company’s selective small molecule inhibitor targeting CHK1 and CHK2, currently in registrational-intent Phase 2 clinical trials. The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.

Key Points: 
  • The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.
  • “We leverage this distinctive capability to create drug-tailored OncoSignature assays as a companion diagnostic aiming to identify and treat patients most likely to benefit from treatment.
  • Biomarker candidates were initially evaluated through pathway reconstitution and in cellular functional assays, after which they were assembled into the ACR-368 OncoSignature assay for further functional validation.
  • These data support the use of the company’s ACR-368 OncoSignature assay in its ongoing registrational-intent Phase 2 clinical trials, and demonstrate the distinctive, practical application of the company’s AP3 platform.

Optilogic's Groundbreaking Sensitivity at Scale Enables Large-Scale Sensitivity Analysis With a Single Click

Retrieved on: 
Thursday, September 21, 2023

ANN ARBOR, Mich., Sept. 21, 2023 /PRNewswire/ -- Supply chain network design software innovator, Optilogic, is making true large-scale sensitivity analysis possible with Sensitivity at Scale, which runs hundreds or thousands of sensitivity scenarios in parallel with a single click.

Key Points: 
  • Sensitivity at Scale runs hundreds or thousands of sensitivity scenarios in parallel with a single click in its SaaS-based Cosmic Frog supply chain design platform.
  • ANN ARBOR, Mich., Sept. 21, 2023 /PRNewswire/ -- Supply chain network design software innovator, Optilogic , is making true large-scale sensitivity analysis possible with Sensitivity at Scale , which runs hundreds or thousands of sensitivity scenarios in parallel with a single click.
  • This groundbreaking innovation in supply chain sensitivity analysis is available today in Optilogic Cosmic Frog , the only 100-percent SaaS-native supply chain design platform.
  • Cosmic Frog removes these barriers by enabling large-scale sensitivity analysis with a single click of the "Sensitivity at Scale" button.

QSM Diagnostics Enters Distribution Agreement with Deiko

Retrieved on: 
Tuesday, July 25, 2023

BOSTON, July 25, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Deiko, a holding company with over 30 years of experience, specializing in the distribution of consumables for veterinarians.

Key Points: 
  • BOSTON, July 25, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Deiko, a holding company with over 30 years of experience, specializing in the distribution of consumables for veterinarians.
  • "At Deiko, we are always looking to innovate when it comes to animal care and health.
  • That's why it is very important for us to have a strategic partner like QSM Diagnostics, as we recognize the importance of proper and timely diagnosis of bacterial infections.
  • "We're very excited to partner with Deiko and their amazing team," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.

QSM Diagnostics Inks Distribution Agreement with Penn Veterinary Supply

Retrieved on: 
Friday, June 16, 2023

BOSTON, June 16, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.

Key Points: 
  • BOSTON, June 16, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics , a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Penn Veterinary Supply , an independent U.S. regional distributor of veterinary products and services.
  • The distribution agreement will enable practices in Penn Veterinary's Supply network access to QSM Diagnostics suite of products.
  • "We love Penn Vet's dedication to providing value for their partners," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.
  • "This partnership will allow us to provide veterinarians more quality options for how bacterial infections are diagnosed and treated by getting our suite of products in their practices."

Standard BioTools to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, June 14, 2023

Dr. King will also participate in a company presentation at 2:35 pm ET.

Key Points: 
  • Dr. King will also participate in a company presentation at 2:35 pm ET.
  • TD Cowen 2nd Annual Tools/Dx Revolution: On Monday, June 26, at 4:20 pm PT, Michael Egholm, President and Chief Executive Officer, will participate in the “Spatial – The Next Frontier: Clinical” Panel.
  • Due to the format of these events, webcasts will not be available.
  • Presentation materials will be available on the Investor Relations page of the company’s website at Events & Presentations .

Akoya to Participate at Two Upcoming Investor Conferences

Retrieved on: 
Monday, June 12, 2023

MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in two upcoming investor conferences.

Key Points: 
  • MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in two upcoming investor conferences.
  • “Pushing the Envelope of Technology with Increased Sensitivity and Higher Plex on the Horizon” Panel on Tuesday, June 20th at 10:30 AM ET
    “Spatial – The Next Frontier: Clinical” Panel on Monday, June 26th at 4:20 PM PT

QSM Diagnostics Signs First Distribution Agreement with Victor Medical Company

Retrieved on: 
Thursday, June 1, 2023

BOSTON, June 1, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Victor Medical Company to expand U.S. channel partnerships for their suite of at-home and in-clinic diagnostic tools. Victor Medical is the largest privately-owned veterinary distributor in California, Arizona, Nevada, and also services states in the Pacific Northwest, providing veterinary clinics with access to quality products and exceptional service. This is the first distribution agreement for QSM Diagnostics and will allow access to their products in all of Victor Medical's 4,000-member practices.

Key Points: 
  • BOSTON, June 1, 2023 /PRNewswire-PRWeb/ -- QSM Diagnostics , a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with Victor Medical Company to expand U.S. channel partnerships for their suite of at-home and in-clinic diagnostic tools.
  • Victor Medical is the largest privately-owned veterinary distributor in California, Arizona, Nevada, and also services states in the Pacific Northwest, providing veterinary clinics with access to quality products and exceptional service.
  • This is the first distribution agreement for QSM Diagnostics and will allow access to their products in all of Victor Medical's 4,000-member practices.
  • "We're very excited to partner with Victor Medical Company and their team of world-class sales representatives," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.